Condition: Advanced Malignancies · Ovarian Cancer · T-cell Lymphoma · Sponsor: BioInvent International AB
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizumab every 3 weeks. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors and subjects with T-cell lymphoma (TCL),
This description comes directly from the study's public registry record.
Susanne Gertsson · +46462868550 · susanne.gertsson@bioinvent.com
Mona Welschof, PhD · +47 97088721 · mona.welschof@bioinvent.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Herlev Hospital | Herlev, Denmark | Recruiting |
| PRA Health Sciences - Hungary | Budapest, Hungary | Active Not Recruiting |
| Magyar Honvédség-Egészségügyi Központ | Budapest, Hungary | Recruiting |
| Debreceni Egyetem Klinikai Központ | Debrecen, Hungary | Withdrawn |
| Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser | Omsk, Russia | Terminated |
| National Medical Research Center VA Almazov | Saint Petersburg, Russia | Withdrawn |
| N.N. Petrov National Medical Research Center of Oncology | Saint Petersburg, Russia | Withdrawn |
| Institut Catala d'oncologia. Hospital Duran I Reynals | Barcelona, Spain | Not Yet Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04752826